4
Participants
Start Date
June 30, 2006
Primary Completion Date
September 30, 2006
Study Completion Date
September 30, 2006
Megestrol acetate concentrated suspension 110 mg/mL
Megestrol acetate concentrated suspension 110 mg/mL given as an oral dose of 550 mg (5 mL) once per day for 56 days, with an optional 28 days extension phase
Megestrol acetate concentrated suspension 60 mg/mL
Megestrol acetate concentrated suspension 60 mg/mL given as an oral dose of 300 mg (5 mL) once per day for 56 days, with an optional 28 days extension phase
Placebo
Placebo oral suspension, 5 mL once daily
Wake Forest University, High Point
Four Seasons Hospice and Paliative Care, Flat Rock
Summit Oncology Associates, Inc., Akron
Pacific Cancer Medical Center, Inc., Anaheim
Lead Sponsor
Collaborators (1)
PRA Health Sciences
INDUSTRY
Par Pharmaceutical, Inc.
INDUSTRY